清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Alzheimer's disease drug development pipeline: 2022

临床试验 医学 药物开发 疾病 药品 药物试验 阿尔茨海默病 重症监护医学 药理学 内科学
作者
Jeffrey L. Cummings,Garam Lee,Pouyan Nahed,Mina Esmail Zadeh Nojoo Kambar,Kate Zhong,Jorge Fonseca,Kazem Taghva
出处
期刊:Alzheimer's & Dementia: Translational Research & Clinical Interventions [Wiley]
卷期号:8 (1) 被引量:108
标识
DOI:10.1002/trc2.12295
摘要

Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline. Results As of January 25, 2022 (index date for this study) there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Disease-modifying therapies represent 83.2% of the total number of agents in trials; symptomatic cognitive enhancing treatments represent 9.8% of agents in trials; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirty-seven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD. Highlights There are 143 drugs in the current Alzheimer's disease (AD) drug development pipeline. Disease-modifying therapies represent 83.2% of the candidate treatments. Current trials require 50,575 participants who will donate 3,878,843 participant-weeks to clinical trials. The biopharmaceutical industry sponsors 50% of all clinical trials including 68% of Phase 3 trials. Sixty-three percent of Phase 3 trials and 46% of Phase 2 trials include non–North American clinical trial site locations indicating the global ecosystem required for AD drug development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
46464发布了新的文献求助10
3秒前
6秒前
ZZ发布了新的文献求助10
11秒前
Eri_SCI完成签到 ,获得积分10
29秒前
Bazinga完成签到,获得积分10
2分钟前
顾矜应助lin.xy采纳,获得10
2分钟前
4分钟前
lin.xy发布了新的文献求助10
4分钟前
lin.xy完成签到,获得积分10
4分钟前
xaopng完成签到,获得积分10
5分钟前
5分钟前
kryzhang发布了新的文献求助10
5分钟前
tingyeh完成签到,获得积分10
6分钟前
宇文傲龙完成签到 ,获得积分10
7分钟前
Eatanicecube完成签到,获得积分10
7分钟前
Richard完成签到 ,获得积分10
8分钟前
爱听歌的书雁完成签到,获得积分10
10分钟前
木子倪发布了新的文献求助30
11分钟前
12分钟前
木子倪发布了新的文献求助30
12分钟前
Owen应助科研通管家采纳,获得10
13分钟前
糊涂的青烟完成签到 ,获得积分10
14分钟前
vitamin完成签到 ,获得积分10
14分钟前
tinner完成签到,获得积分10
14分钟前
可爱的函函应助sunny采纳,获得10
15分钟前
紫熊发布了新的文献求助30
17分钟前
18分钟前
18分钟前
18分钟前
赘婿应助小小怪很聪明采纳,获得10
18分钟前
511完成签到 ,获得积分10
18分钟前
肆肆完成签到,获得积分10
19分钟前
紫熊完成签到,获得积分10
19分钟前
19分钟前
sunny发布了新的文献求助10
19分钟前
20分钟前
sunny完成签到,获得积分10
20分钟前
20分钟前
21分钟前
zsmj23完成签到 ,获得积分0
21分钟前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3063160
求助须知:如何正确求助?哪些是违规求助? 2717940
关于积分的说明 7456727
捐赠科研通 2364292
什么是DOI,文献DOI怎么找? 1253382
科研通“疑难数据库(出版商)”最低求助积分说明 608564
版权声明 596606